New and Exciting Distribution Agreement Between SLS and Roche
News Feb 11, 2013
In order to better serve customers in the transfection market, Roche has decided to enter into an agreement with Scientific Laboratory Supplies Limited (SLS Ltd.) for the distribution of the Roche Applied Science X-tremeGENE transfection reagents including the X-tremeGENE 9 and X-tremeGENE HP.
SLS is a leading supplier of scientific equipment, chemicals and consumables and has a major presence nationally.
Its broad network of representatives will be able to visit Roche customers regularly about X-tremeGENE products, providing a higher level of service pre and post sales than we are currently able.
The new arrangement reflects Roche’s commitment to delivering first class support to customers whom, we believe, will see immediate benefits as an outcome.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.